Article Text

Download PDFPDF
Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer
  1. J. S. NIELSEN*,
  2. E. JAKOBSEN,
  3. B. HØLUND,
  4. K. BERTELSEN§ and
  5. A. JAKOBSEN
  1. *University of Southern Denmark, Vejle, Denmark
  2. Department of Oncology, Vejle Hospital, Vejle, Denmark
  3. Department of Pathology, Odense University Hospital, Odense, Denmark
  4. §Department of Oncology, Odense University Hospital, Odense, Denmark
  1. Address correspondence and reprint requests to: Professor Anders Jakobsen, Department of Oncology, Vejle Hospital, Vejle, DK 7100, Denmark. Email: aja{at}vs.vejleamt.dk

Abstract

The objective of the study was to evaluate the prognostic effect of p53, Her-2, and EGFR in borderline and epithelial ovarian cancer. Tumor tissue from 85 patients with borderline and 783 patients with epithelial ovarian cancer stage I-IV were analyzed immunohistochemically for p53 positivity and over-expression of Her-2 and EGFR. In the ovarian cancer (OC) group 415 patients (53%) had p53-positive tumors, 272 (35%) had tumors with Her-2 over-expression, and 483 (62%) had over-expression of EGFR. In the OC group the classical prognostic factors (older age, higher FIGO stage, and poorer differentiated stage) had significant prognostic value in both uni- and multivariate analyses. Multivariate analyses in the OC group proved p53 positivity to increase mortality significantly depending on the grade of the tumor. Her-2 likewise increased the risk of mortality significantly in this group depending on the grade of the tumor. EGFR on the other hand did not have any additional prognostic effect in the OC group after adjustment for the classical prognostic and molecular factors was made. In the borderline group Her-2 and EGFR over-expression in combination, adjusted for age and p53, significantly improved the prognosis.

  • borderline
  • ovarian cancer
  • prognosis
  • p53
  • Her-2
  • EGFR

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.